Biomarker Research

OTHER2 trials

Sponsors

M.D. Anderson Cancer Center, Attikon Hospital

Conditions

Advanced CancersDNA DamageDNA Double Strand BreakHNSCC

Unknown Phase

Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients

M.D. Anderson Cancer CenterAdvanced Cancers

Start: 2010-09-27End: 2020-09-27Target: 2000Updated: 2020-01-10

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Attikon HospitalDNA Damage, DNA Double Strand Break, HNSCC

Start: 2018-05-01End: 2020-05-01Target: 50Updated: 2018-08-29

Related Papers

11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

The Oncologist2026-09-01

Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma.

2025-05-232 citations

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.

2023-12-2846 citations

Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).

Journal of Clinical Oncology2019-05-202 citations